Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

One-year outcome of intense pulsed light therapy for refractory meibomian gland dysfunction in patients continuously exposed to topical glaucoma medications: a comparative study

IPL therapy is effective for treating refractory MGD in both glaucoma and non-glaucoma patients, with significant improvements in dry eye symptoms, tear film stability and meibum quality.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors compared one-year outcomes of intense pulsed light therapy with meibomian gland expression in 21 glaucoma patients and 21 non-glaucoma patients with refractory meibomian gland dysfunction, using a retrospective design. Both groups showed improved dry eye symptoms and tear film stability, but only the non-glaucoma group kept some improvements, and lid telangiectasia improved less in the glaucoma group at 12 months.

Who or what was studied
Adults with refractory meibomian gland dysfunction: 21 glaucoma patients using topical hypotensive agents and 21 non-glaucoma patients (mean age about 64 years), matched by propensity score.
Limits stated in the abstract
The study was retrospective with small groups, and the abstract reports only comparative differences without a control group receiving no treatment.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

To evaluate the one-year effect of intense pulsed light (IPL) for refractory meibomian gland dysfunction (MGD) between patients treated with and without topical hypotensive agents.

Methods

This retrospective study included 21 MGD eyes of 21 glaucoma patients (age, 64.38 ± 13.74 years) and 21 MGD eyes of 21 non-glaucoma patients (age, 63.90 ± 13.50 years). Both arms received IPL therapy with meibomian gland expression (MGX). Propensity score matching ensured baseline comparability. Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, tear film breakup time (TBUT), lid telangiectasia, corneal staining, meibum quality and expressibility were assessed at baseline, 3-, 6-, 9- and 12-months post-treatment.

Results

Both groups showed significant improvement in SPEED score and TBUT at 9 months, but only the non-glaucoma group maintained these improvements at 12 months (P < 0.01). While meibum quality improved in both groups at 12 months, significant improvement in lid telangiectasia and meibum expressibility was observed only in the non-glaucoma group. At 12 months, the non-glaucoma group showed less lid telangiectasia than the glaucoma group (P = 0.009). No other intergroup differences were found in other outcomes. Neither group showed significant improvement in corneal staining throughout the follow-up period.

Conclusions

IPL therapy is effective for treating refractory MGD in both glaucoma and non-glaucoma patients, with significant improvements in dry eye symptoms, tear film stability and meibum quality. However, patients on continuous hypotensive agents showed less improvement in lid telangiectasia at 12 months, suggesting that chronic hypotensive medication use may affect treatment efficacy.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Dry eye. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies